Clinical outcomes for patients with high-risk disease treated preemptively with TAA-T after BMT (n = 12). (A) Swimmer plot showing clinical outcomes of patients treated preemptively with TAA-T infusion for high-risk disease after BMT, categorized by dose level (1-4). All patients were in CCR at the time of TAA-T infusion. The dotted line denotes 1 year postinfusion. (B) Kaplan-Meier curve estimating LFS postinfusion of preemptively treated patients. Median LFS has not been reached for all patients. Patients who relapsed in the first 6 months post–TAA-T infusion (n = 2) had median LFS of 99 days; median LFS for patients in persistent remission (no relapse or PD within 6 months of TAA-T infusion [n = 9]) has not been reached. (C) Kaplan-Meier curve estimating OS postinfusion of preemptively treated patients. Median OS has not been reached for all patients.